Analysts Set HealthEquity, Inc. (NASDAQ:HQY) Price Target at $107.23

Shares of HealthEquity, Inc. (NASDAQ:HQY) have been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $107.23.

A number of equities research analysts have recently commented on the company. Barrington Research reiterated an “outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Friday, September 20th. Bank of America boosted their price objective on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. BTIG Research boosted their price objective on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Deutsche Bank Aktiengesellschaft boosted their price objective on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th.

HealthEquity Trading Down 0.4 %

NASDAQ HQY opened at $104.25 on Friday. The stock has a market capitalization of $9.10 billion, a price-to-earnings ratio of 86.88, a PEG ratio of 1.61 and a beta of 0.52. HealthEquity has a one year low of $62.10 and a one year high of $105.73. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The business’s fifty day moving average is $87.22 and its 200-day moving average is $81.73.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.16. The company had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. Equities research analysts predict that HealthEquity will post 2.27 EPS for the current year.

Insider Buying and Selling

In related news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now owns 54,719 shares in the company, valued at $4,540,582.62. The trade was a 13.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Frank Corvino sold 1,039 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the sale, the director now directly owns 3,784 shares of the company’s stock, valued at $363,642.40. This trade represents a 21.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,536 shares of company stock worth $884,517. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Several institutional investors and hedge funds have recently bought and sold shares of HQY. Wasatch Advisors LP grew its stake in shares of HealthEquity by 6.6% in the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock worth $635,065,000 after purchasing an additional 483,269 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of HealthEquity by 16.0% during the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after buying an additional 325,906 shares during the period. Generate Investment Management Ltd purchased a new position in shares of HealthEquity during the second quarter valued at approximately $24,184,000. Vaughan Nelson Investment Management L.P. raised its holdings in shares of HealthEquity by 36.7% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after acquiring an additional 226,563 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in HealthEquity by 924.2% in the second quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock worth $18,983,000 after acquiring an additional 198,718 shares during the period. 99.55% of the stock is currently owned by institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.